Tumor necrosis factor alpha (TNF-alpha) is a signaling molecule that interacts with one of two receptors on cells targeted for apoptosis. The apoptotic signal is transduced inside these cells by cytoplasmic adaptor proteins. This protein is a death domain-containing adaptor protein that interacts with the death domain of TNF-alpha receptor 1 to activate mitogen-activated protein kinase (MAPK) and propagate the apoptotic signal. It is membrane-bound and expressed at a higher level in neoplastic cells than in normal cells. Several transcript variants encoding different isoforms have been described for this gene.
Human MAP kinase-activating death domain protein (MADD) ELISA Kit employs a two-site sandwich ELISA to quantitate MADD in samples. An antibody specific for MADD has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyMADD present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for MADD is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of MADD bound in the initial step. The color development is stopped and the intensity of the color is measured.
Human MAP kinase-activating death domain protein (MADD) ELISA Kit listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Find more details at http://www.abbkine.com/product/human-map-kinase-activating-death-domain-protein-madd-elisa-kit-kte61755/
bio-equip.cn
Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.